Additionally, by reducing prolactin levels, dopamine agonists may mitigate prolactin-induced hepatic glucose production and adipose tissue dysfunction, both of which are implicated in metabolic dysregulation in PCOS [239]. Here, PRL is linked to polycystic ovary syndrome.